Journal of Neuro-Oncology

, Volume 77, Issue 3, pp 315–320

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

  • Nicole E. Marshall
  • Karla V. Ballman
  • John C. Michalak
  • Paula J. Schomberg
  • Gary V. Burton
  • Howard M. Sandler
  • Terrence L. Cascino
  • Kurt A. Jaeckle
  • Jan C. Buckner
Clinical–patient studies

DOI: 10.1007/s11060-005-9049-1

Cite this article as:
Marshall, N.E., Ballman, K.V., Michalak, J.C. et al. J Neurooncol (2006) 77: 315. doi:10.1007/s11060-005-9049-1

Summary

Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic toxicities were recorded at each visit. Results: 56% of patients had hearing loss at baseline. 13% and 50% of patients experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13% of those on arms C and D experiencing significant ototoxicity (≥ grade 3) at 6 months. Increasing age was associated with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.

Keywords

accelerated radiation therapy glioblastoma ototoxicity of cisplatin 

Copyright information

© Springer Science + Business Media 2005

Authors and Affiliations

  • Nicole E. Marshall
    • 1
  • Karla V. Ballman
    • 1
  • John C. Michalak
    • 2
  • Paula J. Schomberg
    • 1
  • Gary V. Burton
    • 3
  • Howard M. Sandler
    • 3
  • Terrence L. Cascino
    • 1
  • Kurt A. Jaeckle
    • 4
  • Jan C. Buckner
    • 1
    • 5
  1. 1.Mayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Siouxland Hematology–Oncology AssociatesSioux CityUSA
  3. 3.SWOG – University of MichiganAnn ArborUSA
  4. 4.Mayo Clinic JacksonvilleJacksonvilleUSA
  5. 5.Mayo ClinicRochesterUSA

Personalised recommendations